Comparison of the effects of amitriptyline and paroxetine in the treatment of fibromyalgia syndrome

WOS: 000179727900007The aim of this study is to research the efficiency and the side effects of paroxetine, which is a selective serotonin re-uptake inhibitor (SSRI), and to compare it with amitriptyline, whose efficiency in fibromyalgia syndrome (FMS) is well known. The 40 FMS-diagnosed patients that were involved in the research were separated into two groups randomly. The patients within the first group were given paroxetine tablets (for the first weeks 20 mg/day, later 40 mg/day); those within the second group were given amitriptyline drage (for the first two weeks 10 mg/day, later 20 mg/day). The treatment continued for two months. All of the patients were evaluated by a physician, who was not aware of the therapy options, in the 2(nd), 4(th) and 8(th) weeks with regard to fatigue, morning stiffness, sleep disturbances, paraesthesia, headaches, tender point count and score, severity of global pain, Beck depression index, global efficiency and tolerance according to the patient and the physician's judgments. It is observed that paroxetine has shown good efficiency in treating the symptoms of FMS with the exception of fatigue (p < 0.5), but amitriptyline works better. The most important side effect of paroxetine is sexual dysfunction. Paroxetine therefore can be used as an alternative drug in FMS when the patients cannot use amitriptyline for any reason

THE EFFECTIVENESS OF THE LOWER DOSE OF LASER TREATMENT ON KNEE OSTEOARTHRITIS

Annual European Congress of Rheumatology -- JUN 14-17, 2017 -- Madrid, SPAINWOS: 00041318140452

Bone mineral density in mild and advanced ankylosing spondylitis

WOS: 000183950300003PubMed ID: 12833574To compare the bone mineral density (BMD) and determine the frequency of osteoporosis in mild and advanced ankylosing spondylitis (AS) cases. Seventy three patients with AS were enrolled in this study. The BMD was analyzed at the lumbar spine and hip by dual energy X-ray absorptiometry. The patients were diagnosed as being "normal, osteopenia, or osteoporosis" according to the WHO classification. Using the BASRI-lumbar and BASRI-hip scores, the patients were grouped in mild and advanced AS categories. The mean BMD in the lumbar spine and hip of patients with mild and advanced AS was similar (p>0.05). While 61.6% of the patients were found to have osteopenia or osteoporosis in the lumbar spine, 46.6% had osteopenia or osteoporosis in the total hip. Of the patients with advanced AS 54.3% had osteopenia or osteoporosis in the lumbar spine, 75% in the total hip. Of the patients with mild AS patients had 68.4% osteopenia or osteoporosis in the lumbar spine, and 42.3% in the total hip. The osteopenia or osteoporosis frequency of the mild and advanced cases of AS in the lumbar spine was similar (p>0.05). In the advanced AS patients, osteopenia or osteoporosis frequency was significantly higher in the total hip than in the mild AS patients (p<0.05). In conclusion, there was evidence of osteoporosis in both the advanced AS and mild AS patients. The reason why the anteroposterior lumbar DXA results in the advanced AS patients were similar to the mild ones may be due to the existence of syndesmophytes and ligament calcification. In these cases, it is more convenient to use a hip DXA for assessing the extent of osteoporosis

The comparison of the effects of vitamin D3 and alphacalcidiol with dexa in osteoporosis

WOS: 00017561920015

The effectiveness and tolerability of alendronate in case of postmenopausal osteoporosis

WOS: 00008834810048